A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

then pembrolizumab alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. Pembrolizumab, also known as Keytruda, is given as an infusion and is a monoclonal antibody which ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

in a review of the topic at the recent World Conference on Lung Cancer. But how does a large molecule, like pembrolizumab, reach the brain? The blood-brain barrier, which is composed of tightly ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Immutep Limited has released promising results from its INSIGHT-003 trial, showcasing the efficacy of its immunotherapy treatment, eftilagimod alpha, in combination with pembrolizumab and chemotherapy ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...